237 related articles for article (PubMed ID: 37347276)
1. Transcriptomic profiling of Parkinson's disease brains reveals disease stage specific gene expression changes.
Cappelletti C; Henriksen SP; Geut H; Rozemuller AJM; van de Berg WDJ; Pihlstrøm L; Toft M
Acta Neuropathol; 2023 Aug; 146(2):227-244. PubMed ID: 37347276
[TBL] [Abstract][Full Text] [Related]
2. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
[TBL] [Abstract][Full Text] [Related]
3. Lewy body-related alpha-synucleinopathy in the aged human brain.
Jellinger KA
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1219-35. PubMed ID: 15480835
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
5. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
Jellinger KA
Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530
[TBL] [Abstract][Full Text] [Related]
6. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
8. Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology.
Pihlstrøm L; Shireby G; Geut H; Henriksen SP; Rozemuller AJM; Tunold JA; Hannon E; Francis P; Thomas AJ; Love S; Mill J; van de Berg WDJ; Toft M
Nat Commun; 2022 Aug; 13(1):4932. PubMed ID: 35995800
[TBL] [Abstract][Full Text] [Related]
9. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
10. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
[TBL] [Abstract][Full Text] [Related]
11. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
[TBL] [Abstract][Full Text] [Related]
12. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
13. A critical reappraisal of current staging of Lewy-related pathology in human brain.
Jellinger KA
Acta Neuropathol; 2008 Jul; 116(1):1-16. PubMed ID: 18592254
[TBL] [Abstract][Full Text] [Related]
14. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
[TBL] [Abstract][Full Text] [Related]
15. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
16. Pathology-associated change in levels and localization of SIDT2 in postmortem brains of Parkinson's disease and dementia with Lewy bodies patients.
Fujiwara Y; Kabuta C; Sano T; Murayama S; Saito Y; Kabuta T
Neurochem Int; 2022 Jan; 152():105243. PubMed ID: 34800582
[TBL] [Abstract][Full Text] [Related]
17. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
18. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
Wakabayashi K
Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
[TBL] [Abstract][Full Text] [Related]
19. Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease.
Garcia-Esparcia P; Hernández-Ortega K; Koneti A; Gil L; Delgado-Morales R; Castaño E; Carmona M; Ferrer I
Acta Neuropathol Commun; 2015 Dec; 3():76. PubMed ID: 26621506
[TBL] [Abstract][Full Text] [Related]
20. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
